{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:11:21Z","timestamp":1778641881739,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the CAMS Innovation Fund for Medical Sciences","award":["No. 2021-I2M-1-014 and No. 2022-I2M-2-002"],"award-info":[{"award-number":["No. 2021-I2M-1-014 and No. 2022-I2M-2-002"]}]},{"name":"the CAMS Innovation Fund for Medical Sciences","award":["No. 2021-I2M-1-014 and No. 2022-I2M-2-002"],"award-info":[{"award-number":["No. 2021-I2M-1-014 and No. 2022-I2M-2-002"]}]},{"name":"the CAMS Innovation Fund for Medical Sciences","award":["No. 2021-I2M-1-014 and No. 2022-I2M-2-002"],"award-info":[{"award-number":["No. 2021-I2M-1-014 and No. 2022-I2M-2-002"]}]},{"name":"the CAMS Innovation Fund for Medical Sciences","award":["No. 2021-I2M-1-014 and No. 2022-I2M-2-002"],"award-info":[{"award-number":["No. 2021-I2M-1-014 and No. 2022-I2M-2-002"]}]},{"name":"the CAMS Innovation Fund for Medical Sciences","award":["No. 2021-I2M-1-014 and No. 2022-I2M-2-002"],"award-info":[{"award-number":["No. 2021-I2M-1-014 and No. 2022-I2M-2-002"]}]},{"name":"the CAMS Innovation Fund for Medical Sciences","award":["No. 2021-I2M-1-014 and No. 2022-I2M-2-002"],"award-info":[{"award-number":["No. 2021-I2M-1-014 and No. 2022-I2M-2-002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15947-x","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T08:07:00Z","timestamp":1775117220000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment for metastatic triple-negative breast cancer with homologous recombination deficiency: a Bayesian network meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Hangcheng","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Sa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiran","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"issue":"1","key":"15947_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","volume":"15","author":"Y Li","year":"2022","unstructured":"Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol OncolJ Hematol Oncol. 2022;15(1):121.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"15947_CR2","doi-asserted-by":"crossref","unstructured":"Ye F, Dewanjee S, Li Y, Jha NK, Chen ZS, Kumar A et al. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023;22(1):105.","DOI":"10.1186\/s12943-023-01805-y"},{"issue":"20","key":"15947_CR3","doi-asserted-by":"publisher","first-page":"6113","DOI":"10.1158\/1078-0432.CCR-16-3227","volume":"23","author":"J Sun","year":"2017","unstructured":"Sun J, Meng H, Yao L, Lv M, Bai J, Zhang J, et al. Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23(20):6113\u20139.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"2","key":"15947_CR4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrc.2015.21","volume":"16","author":"CJ Lord","year":"2016","unstructured":"Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer. 2016;16(2):110\u201320.","journal-title":"Nat Rev Cancer"},{"key":"15947_CR5","doi-asserted-by":"publisher","unstructured":"YuanP, Ma N, Xu B. Poly (adenosine diphosphate-ribose) polymerase inhibitors in the treatment of triple-negative breast cancer with homologous repair deficiency. Med Res Rev. 2024;44(6):2774\u201392. https:\/\/doi.org\/10.1002\/med.22058","DOI":"10.1002\/med.22058"},{"key":"15947_CR6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"10;377(6)","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;10;377(6):523\u201333.","journal-title":"N Engl J Med"},{"issue":"5","key":"15947_CR7","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","volume":"24","author":"A Tutt","year":"2018","unstructured":"Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, et al. Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018;24(5):628\u201337.","journal-title":"Nat Med"},{"key":"15947_CR8","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"15947_CR9","doi-asserted-by":"crossref","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384.","DOI":"10.7326\/M14-2385"},{"key":"15947_CR10","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"19;283(15)","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000;19;283(15):2008\u201312.","journal-title":"JAMA"},{"key":"15947_CR11","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"issue":"9","key":"15947_CR12","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"key":"15947_CR13","doi-asserted-by":"crossref","unstructured":"Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;19(7454):1490.","DOI":"10.1136\/bmj.328.7454.1490"},{"issue":"4","key":"15947_CR14","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088\u2013101.","journal-title":"Biometrics"},{"issue":"2","key":"15947_CR15","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","volume":"56","author":"S Duval","year":"2000","unstructured":"Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455\u201363.","journal-title":"Biometrics"},{"key":"15947_CR16","doi-asserted-by":"crossref","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.","DOI":"10.1186\/1745-6215-8-16"},{"issue":"4","key":"15947_CR17","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/ijc.34525","volume":"153","author":"E Senkus","year":"2023","unstructured":"Senkus E, Delaloge S, Domchek SM, Conte P, Im SA, Xu B, et al. Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial. Int J Cancer. 2023;153(4):803\u201314.","journal-title":"Int J Cancer"},{"issue":"4","key":"15947_CR18","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/annonc\/mdz012","volume":"30","author":"ME Robson","year":"2019","unstructured":"Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol Off J Eur Soc Med Oncol. 2019;30(4):558\u201366.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"8","key":"15947_CR19","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gon\u00e7alves A, Lee KH, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018;379(8):753\u201363.","journal-title":"N Engl J Med"},{"issue":"11","key":"15947_CR20","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","volume":"31","author":"JK Litton","year":"2020","unstructured":"Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gon\u00e7alves A, et al. Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020;31(11):1526\u201335.","journal-title":"Ann Oncol"},{"issue":"2","key":"15947_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.20892\/j.issn.2095-3941.2022.0525","volume":"20","author":"Y Chen","year":"2023","unstructured":"Chen Y, Wang X, Du F, Yue J, Si Y, Zhao X, et al. Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer. Cancer Biol Med. 2023;20(2):155\u201368.","journal-title":"Cancer Biol Med"},{"issue":"8","key":"15947_CR22","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/jnci\/djab004","volume":"113","author":"LA Emens","year":"2021","unstructured":"Emens LA, Molinero L, Loi S, Rugo HS, Schneeweiss A, Di\u00e9ras V, et al. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. J Natl Cancer Inst. 2021;113(8):1005\u201316.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"15947_CR23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1001\/jamaoncol.2023.5424","volume":"10","author":"BD Lehmann","year":"2024","unstructured":"Lehmann BD, Abramson VG, Dees EC, Shah PD, Ballinger TJ, Isaacs C, et al. Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial. JAMA Oncol. 2024;10(2):193\u2013201.","journal-title":"JAMA Oncol"},{"issue":"9","key":"15947_CR24","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Annals of Oncology. 2021;32(9):1148\u201356.","journal-title":"Annals of Oncology"},{"issue":"8","key":"15947_CR25","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1093\/annonc\/mdy209","volume":"29","author":"J Zhang","year":"2018","unstructured":"Zhang J, Lin Y, Sun XJ, Wang BY, Wang ZH, Luo JF, et al. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Ann Oncol Off J Eur Soc Med Oncol. 2018;29(8):1741\u20137.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"2","key":"15947_CR26","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1470-2045(22)00739-2","volume":"24","author":"E Rodler","year":"2023","unstructured":"Rodler E, Sharma P, Barlow WE, Gralow JR, Puhalla SL, Anders CK, et al. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2023;24(2):162\u201374.","journal-title":"Lancet Oncol"},{"issue":"11","key":"15947_CR27","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1038\/s41416-022-02003-1","volume":"127","author":"W Jacot","year":"2022","unstructured":"Jacot W, Lusque A, Vicier C, Mailliez A, de La Motte Rouge T, Cabel L, et al. Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1\/2 mutations. Br J Cancer. 2022;127(11):1963\u201373.","journal-title":"Br J Cancer"},{"key":"15947_CR28","doi-asserted-by":"publisher","first-page":"S194","DOI":"10.1016\/j.annonc.2022.03.180","volume":"33","author":"A Tutt","year":"2022","unstructured":"Tutt A, Nowecki Z, Szoszkiewicz R, Im SA, Arkenau HT, Armstrong A, et al. 161O VIOLETTE: Randomised phase II study of olaparib (ola) + ceralasertib (cer) or adavosertib (ada) vs ola alone in patients (pts) with metastatic triple-negative breast cancer (mTNBC). Ann Oncol. 2022;33:S194\u20135.","journal-title":"Ann Oncol"},{"issue":"10","key":"15947_CR29","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1470-2045(20)30447-2","volume":"21","author":"V Di\u00e9ras","year":"2020","unstructured":"Di\u00e9ras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(10):1269\u201382.","journal-title":"Lancet Oncol"},{"issue":"1","key":"15947_CR30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/annonc\/mdx505","volume":"29","author":"HS Han","year":"2018","unstructured":"Han HS, Di\u00e9ras V, Robson M, Pal\u00e1cov\u00e1 M, Marcom PK, Jager A, et al. Veliparib with temozolomide or carboplatin\/paclitaxel versus placebo with carboplatin\/paclitaxel in patients with BRCA1\/2 locally recurrent\/metastatic breast cancer: randomized phase II study. Ann Oncol Off J Eur Soc Med Oncol. 2018;29(1):154\u201361.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"15947_CR31","first-page":"103756","volume":"76","author":"F Cardoso","year":"2024","unstructured":"Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, Matos L, Gelmon K, Aapro MS, et al. 7th international consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast Off J Eur Soc Mastology. 2024;76:103756. 6.","journal-title":"Breast Off J Eur Soc Mastology"},{"key":"15947_CR32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2019.02.007","volume":"45","author":"C Belli","year":"2019","unstructured":"Belli C, Duso BA, Ferraro E, Curigliano G. Homologous recombination deficiency in triple negative breast cancer. The Breast. 2019;45:15\u201321.","journal-title":"The Breast"},{"issue":"9","key":"15947_CR33","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1158\/1078-0432.CCR-06-3039","volume":"13","author":"CK Donawho","year":"2007","unstructured":"Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13(9):2728\u201337.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"44","key":"15947_CR34","doi-asserted-by":"publisher","first-page":"17079","DOI":"10.1073\/pnas.0806092105","volume":"105","author":"S Rottenberg","year":"2008","unstructured":"Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AOH, Zander SAL, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A. 2008;105(44):17079\u201384.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"15947_CR35","volume":"1877","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Hu Y, Tang C, Guan X, Zhang W. Platinum-based systematic therapy in triple-negative breast cancer. Biochimica et Biophysica Acta (BBA). 2022;1877(1):188678.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"15947_CR36","doi-asserted-by":"crossref","unstructured":"Z W, Pwg ROYW, Am W. H, J G, ATR inhibitor AZD6738 (ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib. Cancer Res. 2022;82(6). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35078817\/. Cited 2024 Dec 2.","DOI":"10.1158\/0008-5472.CAN-21-2997"},{"key":"15947_CR37","doi-asserted-by":"crossref","unstructured":"Cardillo TM, Sharkey RM, Rossi DL, Arrojo R, Mostafa AA, Goldenberg DM. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1\/2-wild-type Triple-Negative Breast Cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23(13):3405\u201315.","DOI":"10.1158\/1078-0432.CCR-16-2401"},{"key":"15947_CR38","doi-asserted-by":"crossref","unstructured":"Bardia A, Sun S, Thimmiah N, Coates JT, Wu B, Abelman RO et al. Antibody\u2013drug conjugate sacituzumab govitecan enables a sequential TOP1\/PARP inhibitor therapy strategy in patients with breast cancer. Clin Cancer Res. 2024;30(14):2917\u201324.","DOI":"10.1158\/1078-0432.CCR-24-0428"},{"key":"15947_CR39","doi-asserted-by":"publisher","first-page":"e2100456","DOI":"10.1200\/PO.21.00456","volume":"6","author":"TA Yap","year":"2022","unstructured":"Yap TA, Hamilton E, Bauer T, Dumbrava EE, Jeselsohn R, Enke A, et al. Phase ib SEASTAR study: combining rucaparib and sacituzumab govitecan in patients with cancer with or without mutations in homologous recombination repair genes. JCO Precis Oncol. 2022;6:e2100456.","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"15947_CR40","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1158\/1078-0432.CCR-16-1546","volume":"23","author":"JM Lee","year":"2017","unstructured":"Lee JM, Peer CJ, Yu M, Amable L, Gordon N, Annunziata CM, et al. Sequence-specific pharmacokinetic and pharmacodynamic phase I\/ib study of olaparib tablets and carboplatin in women\u2019s cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23(6):1397\u2013406.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"10","key":"15947_CR41","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1038\/s41416-023-02226-w","volume":"128","author":"M Beniey","year":"2023","unstructured":"Beniey M, Hubert A, Haque T, Cotte AK, B\u00e9chir N, Zhang X, et al. Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer. Br J Cancer. 2023;128(10):1964\u201375.","journal-title":"Br J Cancer"},{"issue":"2","key":"15947_CR42","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3390\/jpm12020323","volume":"12","author":"Y Chai","year":"2022","unstructured":"Chai Y, Chen Y, Zhang D, Wei Y, Li Z, Li Q, et al. Homologous recombination deficiency (HRD) and BRCA 1\/2 gene mutation for predicting the effect of platinum-based neoadjuvant chemotherapy of early-stage triple-negative breast cancer (TNBC): a systematic review and meta-analysis. J Pers Med. 2022;12(2):323.","journal-title":"J Pers Med"},{"key":"15947_CR43","doi-asserted-by":"publisher","first-page":"175883592210962","DOI":"10.1177\/17588359221096253","volume":"14","author":"L Zhang","year":"2022","unstructured":"Zhang L, Chen Y, Cheng MY, Zhuang X, Zou J, Wei D, et al. Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a systematic review and meta-analysis. Ther Adv Med Oncol. 2022;14:17588359221096253.","journal-title":"Ther Adv Med Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15947-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15947-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15947-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T02:40:59Z","timestamp":1778640059000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15947-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15947"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15947-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"4 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"612"}}